BioRelix Pharmaceuticals Enters Antibacterial Collaboration with Merck & Co., Inc.

NEW HAVEN, Conn.--(BUSINESS WIRE)--BioRelix, Inc. today announced that it has entered into a research collaboration agreement with a subsidiary of Merck & Co., Inc. to identify new antibacterial drug candidates.

MORE ON THIS TOPIC